ZHAOKE OPHTH-B(06622): Beimei lumigan eye drops (Crystal Bei Qing) has been approved for market by the National Medical Products Administration.

ZHAOKE OPHTH-B (06622) announces that the anti-glaucoma drug Bemefirst prostaglandin eye drops (Jingbeiqing) developed and produced by the company has been approved by the National Medical Products Administration (NMPA) for market launch. Bemefirst prostaglandin eye drops (Jingbeiqing) is the first single-dose Bemefirst prostaglandin eye drops in China without preservatives, used to reduce eye pressure in patients with open-angle glaucoma and high ocular pressure. This medication does not contain preservatives, avoiding damage to the ocular surface in glaucoma patients commonly caused by long-term use of preservative-containing medications. At the same time, this medication also helps improve patient comfort during treatment and reduces the risk of preservative-related sensitivities. The once-daily dosing frequency also helps improve patient compliance.